SCHEMBL2015756

SCHEMBL2015756

CN(C)c1ccc2cc(S(=O)(=O)Cl)ccc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NSD2 O96028 1/20 0.47
ALDH1A1 P00352 3/20 0.46
KDM4E B2RXH2 1/20 0.46
HPGD P15428 1/20 0.46
ALOX15 P16050 1/20 0.46
HSD17B10 Q99714 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.44
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
TERT O14746 1/20 0.42
APP P05067 1/20 0.42
HTR6 P50406 2/20 0.41
TDP1 Q9NUW8 2/20 0.39
CA9 Q16790 4/20 0.39
CA2 P00918 4/20 0.39
CA12 O43570 3/20 0.39
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14356134 0.83 NSD2 (0.49) NSD2ALDH1A1KDM4EHPGDALOX15
SCHEMBL5666477 0.82 L3MBTL1 (0.46) ALDH1A1HPGDHSD17B10L3MBTL1HTT
SCHEMBL30357699 0.82 LMNA (0.48) ALDH1A1HSD17B10L3MBTL1TDP1CA9
SCHEMBL2263563 0.82 LMNA (0.48) ALDH1A1HSD17B10L3MBTL1TDP1CA9
SCHEMBL612939 0.81 LMNA (0.58) NSD2L3MBTL1HTTNPSR1NPC1
SCHEMBL28493030 0.81 NSD2 (0.47) NSD2ALDH1A1KDM4EHPGDALOX15
SCHEMBL2763826 0.81 NSD2 (0.69) NSD2ALDH1A1KDM4EHPGDALOX15
Hydrochloric Acid SCHEMBL27908422 0.80 NSD2 (0.67) NSD2ALDH1A1KDM4EHPGDALOX15
SCHEMBL29289316 0.80 NSD2 (0.67) NSD2ALDH1A1KDM4EHPGDALOX15
SCHEMBL295564 0.80 ALDH1A1 (0.61) ALDH1A1KDM4EHPGDALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025129193-A1 GLYCOSYLTRANSFERASES AND RELATED METHODS NEW ENGLAND BIOLABS, INC. (US) 2025-06-19 WO disclosed
WO-2024088879-A1 NANOPARTICLES FOR MEDICAL IMAGING AND TREATMENT UNIVERSITÄT REGENSBURG (DE) 2024-05-02 WO disclosed
EP-3469401-B1 IMAGING TECHNOLOGIES UNIV REGENSBURG (DE) 2024-05-01 EP disclosed
EP-4360661-A1 NANOPARTICLES FOR MEDICAL IMAGING AND TREATMENT Universität Regensburg (DE) 2024-05-01 EP disclosed
US-20230022745-A1 Methods for Labeling a Population of RNA Molecules NEW ENGLAND BIOLABS, INC. (US) 2023-01-26 US disclosed
US-11479766-B2 Methods for labeling a population of RNA molecules NEW ENGLAND BIOLABS, INC. (US) 2022-10-25 US disclosed
EP-3469401-A1 IMAGING TECHNOLOGIES Universitätsklinikum Regensburg (DE) 2019-04-17 EP disclosed
US-20180195061-A1 Methods for Labeling a Population of RNA Molecules NEW ENGLAND BIOLABS, INC. (US) 2018-07-12 US disclosed
EP-3279699-A1 IMAGING TECHNOLOGIES Universitätsklinikum Regensburg (DE) 2018-02-07 EP disclosed
CN-103189063-B therapeutic compositions and methods 宾夕法尼亚州研究基金会 2016-10-19 CN disclosed
WO-2005040759-A2 APPARATUS AND METHODS FOR DETECTING TARGET ANALYTE DAKOTA TECHNOLOGIES, INC. (US) 2005-05-06 WO disclosed
US-5512667-A Trifunctional intermediates for preparing 3'-tailed oligonucleotides DRUG ROYALTY LP1 (CA) 1996-04-30 US disclosed
US-5419966-A Solid support for synthesis of 3'-tailed oligonucleotides MICROPROBE CORPORATION (US) 1995-05-30 US disclosed
EP-0547142-A4 MICROPROBE CORP (US) 1995-01-18 EP disclosed
EP-0547142-A1 SOLID SUPPORT SYNTHESIS OF 3'-TAILED OLIGONUCLEOTIDES VIA A LINKING MOLECULE EPOCH PHARMACEUTICALS, INC. (US) 1993-06-23 EP disclosed
WO-1992003464-A1 SOLID SUPPORT SYNTHESIS OF 3'-TAILED OLIGONUCLEOTIDES VIA A LINKING MOLECULE MICROPROBE CORPORATION (US) 1992-03-05 WO disclosed
US-4168307-A ANTICOAGULANTS MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) 1979-09-18 US disclosed
US-4154828-A ANTITHROMBOGENIC MITSUBISHI CHEMICAL INDUSTRIES, LTD. (JP) 1979-05-15 US disclosed
US-4069329-A INHIBITION AND SUPPRESSION OF THROMBOSIS MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) 1978-01-17 US disclosed
US-4062963-A N2 -naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) 1977-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180195061-A1 Methods for Labeling a Population of RNA Molecules RNGTT, RNMT, MTAP NSD2 2681/4885ALDH1A1 2357/4885KDM4E 1517/4885
US-11479766-B2 Methods for labeling a population of RNA molecules RNGTT, RNMT, MTAP NSD2 2681/4885ALDH1A1 2357/4885KDM4E 1517/4885
US-20230022745-A1 Methods for Labeling a Population of RNA Molecules RNGTT, RNMT, MTAP NSD2 2681/4885ALDH1A1 2357/4885KDM4E 1517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.